Company Quick10K Filing
Artelo Biosciences
10-Q 2020-02-29 Filed 2020-04-13
10-Q 2019-11-30 Filed 2020-01-14
10-K 2019-08-31 Filed 2019-11-25
10-Q 2019-05-31 Filed 2019-07-15
S-1 2019-04-01 Public Filing
10-Q 2019-02-28 Filed 2019-04-15
10-Q 2018-11-30 Filed 2019-01-14
S-1 2018-09-27 Public Filing
10-K 2018-08-31 Filed 2018-11-29
10-Q 2018-05-31 Filed 2018-07-13
10-Q 2018-02-28 Filed 2018-04-16
S-1 2018-01-29 Public Filing
10-Q 2017-11-30 Filed 2018-01-16
10-K 2017-08-31 Filed 2017-11-29
10-Q 2017-05-31 Filed 2017-07-21
10-Q 2017-02-28 Filed 2017-04-14
10-Q 2016-11-30 Filed 2017-01-10
10-K 2016-08-31 Filed 2016-11-29
10-Q 2016-05-31 Filed 2016-07-05
10-Q 2016-02-29 Filed 2016-04-01
10-Q 2015-11-30 Filed 2016-01-14
10-K 2015-08-31 Filed 2015-12-11
10-Q 2015-05-31 Filed 2015-07-15
10-Q 2015-02-28 Filed 2015-04-14
8-K 2020-04-13 Enter Agreement, Exhibits
8-K 2020-03-06 Officers
8-K 2020-02-05 Other Events
8-K 2020-01-14 Earnings, Exhibits
8-K 2019-12-02 Officers
8-K 2019-11-14 Regulation FD, Exhibits
8-K 2019-08-30 Officers
8-K 2019-07-15 Earnings, Exhibits
8-K 2019-06-21 Enter Agreement, Amend Bylaw, Other Events, Exhibits
8-K 2019-04-24 Enter Agreement, Sale of Shares, Other Events
8-K 2019-03-06 Other Events
8-K 2019-03-01 Officers
8-K 2018-10-09 Other Events, Exhibits
8-K 2018-09-12 Enter Agreement, Sale of Shares, Exhibits
8-K 2018-05-30 Regulation FD, Other Events, Exhibits
8-K 2018-01-26 Enter Agreement, Sale of Shares, Exhibits
8-K 2018-01-18 Enter Agreement

Artelo Biosciences Financials

ARTL Metrics, Comps, Filings

Quarterly | Annual

Business

We are a clinical stage biopharmaceutical company focused on developing and commercializing treatments intended to modulate the endocannabinoid system (the "ECS") and related signaling pathways, including a solid-state composition of cannabidiol ("CBD cocrystal"), with improved pharmaceutical-like properties which could have a meaningful impact on cannabinoid-based drug development. Our management team is highly experienced and has a successful history of development, regulatory approval and commercialization of pharmaceuticals.

Our product candidate pipeline broadly leverages leading scientific methodologies to ECS modulation, balances risk across mechanism of action and stages of development, and represents a comprehensive approach in utilizing the power of the ECS to develop pharmaceuticals for patients with unmet healthcare needs. In addition to our cocrystal program, we are currently evaluating ART27.13, which we currently anticipate will enter a Phase 1b/2a trial for cancer related anorexia in the second quarter of 2020, and ART26.12, which is being studied as an endocannabinoid modulator and cancer therapeutic and is in the late pre-clinical stage.

The crystal structure of cannabidiol ("CBD") is known to exhibit polymorphism, or the ability to manifest in different forms. Polymorphism can adversely affect stability, dissolution, and bioavailability of a drug product and thus affect its quality, safety, and efficacy. We have developed a proprietary cocrystal composition of CBD, which we have designated as ART12.11. We believe our cocrystal exists as a single crystal form and as such is anticipated to have advantages over other forms of CBD that exhibit polymorphism. Anticipated advantages of this single crystal structure include improved stability, solubility, and a more consistent absorption profile. We believe these features will result in more consistent bioavailability and may lead to improved safety and efficacy.


Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Equity

Income Statement ($MM Quarterly)

Revenue, G Profit, Net Income

Cash Flow ($MM Quarterly)

Ops, Inv, Fin

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Versartis (VSAR) 8,758 0% -8.7 8% 74,171 10,453 40,000 0 5,749 6,470 -56,239
Apricus Biosciences (APRI) 8,723 -0.4 -177% 5,564 1,451 0 0 -9,832 -9,780 3,440
PetVivo Holdings (PETV) 8,652 -3.8 -453% 648 1,447 0 -82 -2,937 -2,243 8,632
Her Imports (HHER) 8,584 45% -2.3 -57% 6,998 1,048 9,213 4,135 -3,975 -3,711 8,476
Spotlight Innovation (STLT) 8,583 2% -4.7 -50% 7,186 8,344 32 1 -3,613 -2,846 13,490
Eternity Healthcare (ETAH) 8,553 -22.9 -14% 2,720 2,865 0 0 -388 -388 8,906
Torotel (TTLO) 8,394 39% 4.4 18% 12,289 6,879 25,942 10,206 2,253 2,439 10,746
KinerjaPay (KPAY) 8,379 4% -0.5 -395% 4,308 9,409 361 14 -17,021 -16,996 8,254
Artelo Biosciences (ARTL) 2,494 -1.1 -175% 1,153 1,019 0 0 -2,017 -2,017 2,208
Valuesetters (VSTR) 8,306 99% 6.9 54% 2,193 1,554 1,689 1,671 1,177 1,200 8,275
Jade Global Holdings (JADG) 8,280 -49.0 -1,042% 16 441 0 0 -169 -169 8,271
Magellan Gold (MAGE) 8,278 -713% -2.0 -312% 1,473 2,477 32 -232 -4,600 -4,221 8,270
Advanced Voice Recognition Systems (AVOI) 8,261 -175.3 -120% 41 238 0 0 -50 -47 8,252
Sugarmade (SGMD) 8,103 29% -0.9 -53% 22,109 8,136 3,950 1,149 -11,648 -9,858 9,208
Vitalibis (VCBD) 8,075 42% -2.1 -894% 525 1,724 233 98 -4,694 -3,894 8,040
Giga Tronics (GIGA) 8,058 42% 735.4 -4% 8,753 6,345 11,951 5,069 -379 10 7,354
Evans & Sutherland (ESCC) 8,038 35% -3.1 -5% 26,408 19,184 20,873 7,242 -1,242 -994 3,125
Sunstock (SSOK) 7,979 4% -0.6 -2,026% 643 10,583 3,930 170 -13,027 -12,827 7,954
Accelerize (ACLZ) 7,974 59% 0.6 264% 4,998 790 5,458 3,213 13,190 13,245 7,482
Wright Investors (WISH) 7,898 -4.1 -18% 7,976 105 0 0 -1,464 -1,438 5,899

Balance Sheet ($'000)2015-02-282015-05-312015-08-312015-11-302016-02-292016-05-312016-08-312016-11-302017-02-282017-05-312017-08-312017-11-302018-02-282018-05-312018-08-312018-11-302019-02-282019-05-31
Cash813174444411228573412525326337115457286
Accounts Receivable
Inventory
PP&E1111001
Assets8131744444132285744305414013971654841,153
Accounts Payable
Long-Term Debt
Liabilities2023813171033342291361564925326411,1761,019
Stockholders' Equity713151-4-9-14-6-19-114545294385-91-135-475-692134
Income Statement ($'000)2015-02-282015-05-312015-08-312015-11-302016-02-292016-05-312016-08-312016-11-302017-02-282017-05-312017-08-312017-11-302018-02-282018-05-312018-08-312018-11-302019-02-282019-05-31
Revenue0000000000
Cost of Revenue
Gross Profit
R&D33477237332184490184
SG&A0111000418861373110523620658403
Tax000000000000000000
Net Income-6-2-5-15-5-5-4-10-13-97-116-277-628-578-690-557-425-345
Cash Flow ($'000)2015-02-282015-05-312015-08-312015-11-302016-02-292016-05-312016-08-312016-11-302017-02-282017-05-312017-08-312017-11-302018-02-282018-05-312018-08-312018-11-302019-02-282019-05-31
Cash Operating-4-3-14-0-400-22-37-158-170-467-459-514-401-741-589
Cash Investing00000-1-00
Cash Financing71040030254502115812705261741,087419